The sketchy part which Reuters did not point out is that two out of Mylan's five specialty brand-name drugs treat pulmonary problems that are exacerbated by air pollution, a lot of which comes from coal. The company makes Perforomist, an inhaler that treats symptoms of chronic obstructive pulmonary disease (COPD), as well as prevents asthma attacks and exercise-induced bronchial spasm. Multiple studies have linked exacerbated COPD symptoms to air pollution, though those links are suggestive and not conclusive. Mylan is also in the asthma treatment market; the company makes EasiVent, which attaches to asthma inhalers to help the medicine more easily reach the lungs, and it recently failed to get regulatory approval for a generic version of the blockbuster asthma drug Advair. Peer-reviewed science has been linking coal combustion to more severe asthma since at least 1972.